FaDu cell characteristics induced by multidrug resistance

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1189-1195

  Ma, Juke ^a   Lu, Sumei ^b   Yu, Liang ^a   Tian, Jiajun ^b   Li, Jianfeng ^b   Wang, Haibo ^a,b   Xu, Wei ^b  

^a SHANDONG UNIVERSITY   (China)

^b Shandong Clinic Research Institute   (China)

Author keywords

Apoptosis; BCRP ABCG2; FaDu; MDR1 ABCB1; Multidrug resistance

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACRIDINE; BREAST CANCER RESISTANCE PROTEIN; CASPASE 3; CISPLATIN; DOXORUBICIN; FLUOROURACIL; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOPHARYNX CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; MALE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 80053166871     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1418     Document Type: Article

References (27)

1. Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, Ang KK, Gay G, Stewart A and Robinson RA: Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 116: 1-13, 2006. (Pubitemid 44337830)
2. Friboulet L, Pioche-Durieu C, Rodriguez S, Valent A, Souquère S, Ripoche H, Khabir A, Tsao SW, Bosq J, Lo KW and Busson P: Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis. Neoplasia 10: 1183-1194, 2008.
3. Clark JI, Hofmeister C, Choudhury A, Matz G, Collins S, Bastian R, Melian E, Emami B and Petruzzelli G: Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer 92: 2334-2340, 2001. (Pubitemid 33029077)
4. Crown J and O'Leary M: The taxanes: an update. Lancet 355: 1176-1178, 2000. (Pubitemid 30172946)
5. Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol 46: 308-316, 2010.
6. O'Connor R: The pharmacology of cancer resistance. Anticancer Res 27: 1267-1272, 2007.
7. Longley DB and Johnston PG: Molecular mechanisms of drug resistance. J Pathol 205: 275-292, 2005. (Pubitemid 40227997)
8. Rowinsky EK, Donehower RC, Jones RJ and Tucker RW: Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 48: 4093-4100, 1988.
9. Zhang X, Wang X, Song X, Liu C, Shi Y, Wang Y, Afonja O, Ma C, Chen YH and Hang L: Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo. Cancer Sci 101: 2163-2170, 2010.
10. Rodrigues AC, Curi R, Genvigir FD, Hirata MH and Hirata RD: The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells. Acta Pharmacol Sin 30: 956-964, 2009.
11. Stavrovskaya AA and Stromskaya TP: Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry 73: 592-604, 2008. (Pubitemid 351775081)
12. Vasiliou V, Vasiliou K and Nebert DW: Human ATP-binding cassette (ABC) transporter family. Hum Genomics 3: 281-290, 2009.
13. Daood M, Tsai C, Ahdab-Barmada M and Watchko JF: ABC transporter (P-gp/AB-CB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics 39: 211-218, 2008.
14. Abraham I, Jain S, Wu CP, Khanfar MA, Kuang Y, Dai CL, Shi Z, Chen X, Fu L, Ambudkar SV, El Sayed K and Chen ZS: Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Biochem Pharmacol 80: 1497-1506, 2010.
15. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM and Dee-ley RG: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910, 1994. (Pubitemid 24375226)
16. Choi CH: ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 5: 30, 2005.
17. Hughes J and Crowe A: Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci 113: 315-324, 2010.
18. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS and Bates SE: Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br JCancer 89: 1971-1978, 2003. (Pubitemid 37533279)
19. Allen JD and Schinkel AH: Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 1: 427-434, 2002.
20. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH and Bates SE: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113: 2011-2021, 2000. (Pubitemid 30386505)
21. Robey RW, Medina-Pérez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD and Bates SE: Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7: 145-152, 2001. (Pubitemid 32110217)
22. Liu T, Xu F, Du X, Lai D, Liu T, Zhao Y, Huang Q, Jiang L, Huang W, Cheng W and Liu Z: Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Mol Cell Biochem 340: 265-273, 2010.
23. Cisternino S, Mercier C, Bourasset F, Roux F and Scherrmann JM: Expression, up-regulation and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64: 3296-3301, 2004. (Pubitemid 38581436)
24. Choi CH, Kim HS, Rha HS, Jeong JH, Park YH, Min YD, Kee KH and Lim DY: Drug concentration-dependent expression of multidrug resistance-associated protein and P-glycoprotein in the doxorubicin-resistant acute myelogenous leukemia sublines. Mol Cells 9: 314-319, 1999. (Pubitemid 129555798)
25. Friedrich RE, Punke C and Reymann A: Expression of multidrug resistance genes (ABCB1, mrp1, ABCG2) in primary oral squamous cell carcinoma. In Vivo 18: 133-147, 2004.
26. Galimberti S, Guerrini F, Palumbo GA, Consoli U, Fazzi R, Morabito F, Santini V and Petrini M: Evaluation of ABCG2 and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leuk Res 28: 367-372, 2004. (Pubitemid 38199944)
27. Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M and Takebayashi Y: Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 92: 452-458, 2001. (Pubitemid 32427782)